scholarly journals COMPARATIVE CHARACTERISTICS OF SAFETY OF SUBLINGUAL AND PARENTERAL IMMUNOTHERAPY METHODS

2020 ◽  
Vol 17 (34) ◽  
pp. 736-744
Author(s):  
Ulbossyn SALTABAYEVA ◽  
Alexei YUMASHEV
Keyword(s):  
Adverse Reactions ◽  
Specific Immunotherapy ◽  
Sublingual Immunotherapy ◽  
Scientific Evidence ◽  
Adult Population ◽  
Pollen Allergy ◽  
Hay Fever ◽  
Sharp Drop ◽  
Allergen Specific Immunotherapy ◽  
Good Substitute

Among a significant number of allergies, the most common among children and adults is pollen allergy. Pollen allergies primarily lead to irritation of the nose and eyes, but can also cause headaches, weakness, fatigue, and decreased attention span. In an acute allergic reaction, anaphylactic shock can occur, that is, a lifethreatening sharp drop in blood pressure. These and many other consequences of allergic reactions imply the need to create drugs that could cure a person of allergies or stop the manifestation of allergen reactions. The aim of the article was to study the safety of allergen-specific immunotherapy. The research methods included an analysis of the comparison of the effectiveness of two immunotherapy methods, a comparison of the safety of sublingual and parenteral methods of administering allergic vaccines, a comparative assessment of the safety of types of allergen-specific immunotherapy. The study involved 228 patients with varying severity of hay fever, among whom were children from 5 to 18 years old and an adult population (113 patients were men, 115 were women). The study revealed that sublingual immunotherapy increases the safety of treatment and is a good substitute for parenteral immunotherapy, especially in children. The studies have also confirmed well-known scientific evidence on the safety of sublingual immunotherapy in patients with hay fever. It was concluded that sublingual immunotherapy increases the safety of treatment and is a good substitute for the parenteral allergenspecific immunotherapy method, especially in pediatric patients, while having several advantages, such as a significant reduction in adverse reactions, high potency, and a convenient mode of administration, greater patient commitment and trust in treatment, and the elimination of infection transmission.

scholarly journals Clinical efficacy of allergen-specific immunotherapy in children with combined forms of respiratory trees pollen allergy

2016 ◽  
Vol 13 (3) ◽  
pp. 41-48
Author(s):  
Y N Emelina ◽  
I A Tuzankina ◽  
A V Zurochka
Keyword(s):  
Specific Immunotherapy ◽  
Nasal Congestion ◽  
Pollen Allergy ◽  
Hay Fever ◽  
Test Results ◽  
Asthma Control Test ◽  
Allergen Specific Immunotherapy ◽  
Complete Control ◽  
Asthma Symptoms ◽  
Rhino Conjunctivitis

Background. To evaluate the effectiveness of three courses of allergenspecific immunotherapy (ASIT) in children with combined forms of respiratory pollen allergy. Materials and methods. We observed 69 children aged 10,6±0,4 with combined forms of hay fever. All children were randomized and divided into 3 subgroups who received allergen-specific immunotherapy (ASIT) with Fostal, Staloral and water-salted mixed extracts of trees pollen. The comparison group consisted of 16 children with combined forms of hay fever without ASIT. The effectiveness of treatment was assessed by dynamics of the allergic rhino-conjunctivitis symptoms using a visual analogue scale and dynamics of the level of control over the symptoms of bronchial asthma using standardized questionnaires - the Asthma Control Test. Results. The first course of allergen-specific immunotherapy reduced the severity of rhinorrhea by 48%, nasal congestion - by 45,1%, itching eyes - by 40,8%, nasal itching - by 30,6%, complete control of asthma symptoms was achieved in 61,2%; ASIT reduced the likelihood of an uncontrolled flow of asthma in 17,6 times compared with children who did not receive immunotherapy. After three courses of allergen-specific immunotherapy with pollen allergens a decrease of the severity of allergic rhino-conjunctivitis symptoms and increase of the level of asthma symptoms control in all subgroups was shown.

scholarly journals DURATION OF CLINICAL EFFECT OF LOW-DOSE SUBLINGUAL-PERORAL ALLERGEN-SPECIFIC IMMUNOTHERAPY OF BRONCHIAL ASTHMA

2021 ◽  
Vol 19 (2) ◽  
pp. 202-206
Author(s):  
A. V. Sidarenka ◽  
◽  
L. R. Vykhristsenka ◽  
Keyword(s):  
Bronchial Asthma ◽  
Adverse Reactions ◽  
Low Dose ◽  
Specific Immunotherapy ◽  
Adherence To Treatment ◽  
Allergen Specific Immunotherapy ◽  
Negative Effect ◽  
Full Adherence ◽  
Observation Period

Background. Allergen-specific immunotherapy (ASIT) affects the immune response and the clinical course of bronchial asthma (BA). Objective. To evaluate the clinical efficacy of sublingual-oral low-dose ASIT in asthma based on the results of 5-year follow-up. Material and Methods. ASIT was carried out with a mixture of household allergens in 51 patients aged 18-60 years old. The patient's opinion, the number and severity of BA exacerbations, the duration of post-immunotherapeutic remission and the factors influencing it, adherence to treatment, and the safety of treatment were taken into account. Results. The effectiveness of ASIT according to the patient’s opinion: 45.1% - excellent, 49% - good result. In allergic asthma, remission after ASIT was significantly higher than in mixed asthma. Full adherence to treatment (3 courses of ASIT) - in 76.5% (39/51) of patients. There were no adverse reactions during the entire observation period. The mixed BA phenotype, contact with the allergen in everyday life, and smoking had a negative effect. Positive - high compliance to therapy. Conclusions. Sublingual-oral ASIT is an effective and safe method of treating allergic and mixed asthma. The duration of post-immunotherapeutic remission of BA for 3 years was observed after 3 courses of ASIT.

scholarly journals ЕФЕКТИВНІСТЬ СУБЛІНГВАЛЬНОЇ АЛЕРГЕН- СПЕЦИФІЧНОЇ ІМУНОТЕРАПІЇ У ДІТЕЙ З ВЕСНЯНИМ ПОЛІНОЗОМ ТА ПИЛКОВО- ХАРЧОВИМ СИНДРОМОМ

World Science ◽  
2019 ◽  
Vol 2 (3(43)) ◽  
pp. 34-41
Author(s):  
С. Ю. Матвєєва ◽  
Т. Р. Уманець
Keyword(s):  
Specific Immunotherapy ◽  
Birch Pollen ◽  
Pollen Allergy ◽  
Allergen Specific Immunotherapy ◽  
Component Resolved Diagnosis ◽  
Birch Pollen Allergy

The article presents the results of the study on the effectiveness and safety of sublingual allergen-specific immunotherapy in children at the age from 4 to 17 years old with spring polinosis and birch-pollen allergy syndrome, which were assessed using visual analogue and combination scales, provocative tests and the results of component resolved diagnosis.

scholarly journals Current strategies of allergen-specific immunotherapy

2015 ◽  
Vol 12 (4) ◽  
pp. 16-26
Author(s):  
K S Pavlova ◽  
O M Kurbacheva
Keyword(s):  
Grass Pollen ◽  
Specific Immunotherapy ◽  
Pollen Allergy ◽  
Pollen Extract ◽  
Efficacy And Safety ◽  
Grass Pollen Allergy ◽  
Allergen Specific Immunotherapy ◽  
Natural Exposure ◽  
Safety Studies ◽  
Exposure Conditions

The article discusses the principles of the optimal allergovaccine choice for allergen-specific immunotherapy (ASIT) for grass-pollen-allergy patients; reviewed efficacy and safety studies of the standardized mixt five-grass-pollen extract. Relatively grass sensitization is preferred use mixt grass-pollen extract is thus more suitable for specific immunotherapy, as it contains a broader repertoire of the epitopes, which approximate to the natural exposure conditions.

scholarly journals Allergen-specific immunotherapy with pollen allergoids in the treatment ofhay fever in children

2009 ◽  
Vol 6 (1) ◽  
pp. 45-50
Author(s):  
I M Gayduk ◽  
I V Makarova ◽  
O V Trusova ◽  
D V Breykin ◽  
V G Sukhorukova ◽  
...  
Keyword(s):  
Side Effects ◽  
Dose Adjustment ◽  
Specific Immunotherapy ◽  
Hay Fever ◽  
Good Tolerability ◽  
Allergen Specific Immunotherapy ◽  
Course Effectiveness ◽  
Flowering Season ◽  
Systemic Side Effects ◽  
Fever Treatment

Background. The research of effective methods of allergen-specific immunotherapy (ASIT) with good tolerability is important in children with allergic disorders. The aim of the study was to investigate effectiveness and safety of ASIT with pollen allergoids for hay fever treatment in children. Methods. 71 patients 5 to 17 years old with diseases caused by tree pollen sensitization: allergic rhinoconjunctivitis in 36 patients, rhinitis combined with pollen asthma in 17, combined with atopic dermatitis in 1, and pollen asthma in 17, were included in the study. 2 courses of subcutaneous ASIT out of flowering season were conducted in every child using commercially available pollen allergoids. ASIT effectiveness was assessed using 4-point scale where 4 points represents complete disease remission, and 1 point represents lack of effectiveness. Local and systemic side effects were registered as parameters of ASIT safety. Results. Total dose of allergen was 13 768 PNU after the 1st course of ASIT, and 12 700 PNU after the 2nd course. Effectiveness of the 1st course of ASIT was 4,0 points out of 4,0 and of the 2nd course - 4,0 points. Local side effects (infiltration larger than 25 mm, itching and oedema in injection site) in 19,7% patients and systemic side effects (allergic rhinitis exacerbation, urticaria) in 11,3% patients were stopped after allergoid dose adjustment. Conclusion. ASIT with pollen allergoids is effective for hay fever treatment in children. Children with bronchi al asthma are at higher risk for adverse events and need individual dose adjustment.

scholarly journals Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients

2016 ◽  
Vol 29 (4) ◽  
pp. 720-725 ◽  
Author(s):  
Qianhui Qiu ◽  
Mimi Xu ◽  
Chuan Lu ◽  
Jianjun Chen ◽  
Shaohua Chen ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Adverse Reactions ◽  
Specific Immunotherapy ◽  
Therapy Group ◽  
Drug Dosage ◽  
Observation Time ◽  
Allergen Specific Immunotherapy ◽  
Safety And Efficacy ◽  
Conventional Therapy Group ◽  
Rush Immunotherapy

The purpose of this prospective, open-IV clinical trial was to assess the safety and efficacy differences between Rush immunotherapy (RIT) and conventional immunotherapy in Chinese allergic rhinitis (AR) patients. The trial involved 174 patients with AR. They were divided into two groups according to their preference of therapy: RIT or conventional immunotherapy. A total of 162 patients completed a 1-year treatment course. For safety and effectiveness evaluation, the local and systemic adverse reactions were recorded throughout the initial phase of both groups. Weeks 0, 2, 5, and 17 were set as observation time points for immunoglobulin G (IgG) and IgG4. Besides that, another observation time point (Week 11) was added in for a visual analog scale (VAS) and a weekly drug dosage scale. In the RIT group, systemic adverse events of AR were similar to those of the conventional therapy group. LTB4 was descended. The VAS of the RIT group did not show a downward trend clearly, instead Week 5 was higher compared with Week 0. The weekly drug dosage scale did not indicate a significant decline, but there was a clear rise in IgG4 in the RIT group. The safety and efficacy of RIT for AR is positive, but further study is needed for improvement.

Sign in / Sign up

Export Citation Format

Share Document